Monoclonal antibodies against claudin-18 for treatment of cancer

US10017564B2 · kind B2 · utility

Assignee

• Ganymed Pharmaceuticals GmbH · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Dirk Usener · Wiesbaden, DE
• Stefan Fritz · Flonheim, DE
• Christoph Uherek · Seligenstadt, DE
• Gunda Brandenburg · Mainz, DE
• Harald-Gerhard Geppert · Hannover, DE
• Anja Kristina Schröder · Mainz, DE
• Phillippe Thiel · Planegg, DE

Key dates

• Filing date: Mar 14, 2016
• Grant date: Jul 10, 2018
• Expiry date: Mar 14, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.